<DOC>
	<DOCNO>NCT02409355</DOCNO>
	<brief_summary>This randomize , open-label study design evaluate compare safety efficacy atezolizumab gemcitabine + cisplatin carboplatin participant chemotherapy-naive , Stage IV squamous NSCLC .</brief_summary>
	<brief_title>A Study Atezolizumab Compared With Gemcitabine Plus ( + ) Cisplatin Carboplatin Participants With Stage IV Squamous Non-Small Cell Lung Cancer ( NSCLC ) ( IMpower111 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm Stage IV squamous NSCLC Tumor program deathligand 1 ( PDL1 ) expression , determine immunohistochemistry ( IHC ) assay archival tumor tissue tissue obtain screen No prior treatment Stage IV squamous NSCLC Measurable disease define RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic endorgan function Active untreated central nervous system ( CNS ) metastases Untreated inadequately treated spinal cord compression Leptomeningeal disease Uncontrolled pleural effusion , pericardial effusion , ascites Uncontrolled tumorrelated pain Uncontrolled hypercalcemia Any malignancy within 5 year except negligible risk metastasis death Pregnant lactate woman Known hypersensitivity component atezolizumab formulation study medication History autoimmune disease except control , treat hypothyroidism type I diabetes Prior allogeneic bone marrow solid organ transplantation Positive human immunodeficiency virus ( HIV ) test Active hepatitis B C Active tuberculosis Significant cardiovascular disease Severe infection major surgery within 4 week prior randomization Use approve anticancer therapy within 3 week prior treatment Use investigational agent participation another clinical trial within 4 week prior randomization Exposure oral IV antibiotic within 2 week live attenuate vaccine within 4 week prior randomization Prior treatment cluster differentiation ( CD ) 137 agonist immune checkpoint blockade therapy , antiprogrammed death1 ( antiPD1 ) , antiPDL1 therapeutic antibody Treatment immunostimulatory agent within 4 week immunosuppressive agent within 2 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>